BCK2 Antibody

What is BCL2 and what cellular functions does it regulate?

BCL2 (B-cell lymphoma 2) is a key regulator of programmed cell death that functions by suppressing apoptosis in various cell systems, including lymphohematopoietic and neural cells . The protein primarily regulates cell death by controlling mitochondrial membrane permeability, functioning within a feedback loop system with caspases . BCL2 inhibits caspase activity through two primary mechanisms: by preventing cytochrome c release from mitochondria and by binding to the apoptosis-activating factor (APAF-1) . Beyond its canonical role in apoptosis regulation, BCL2 also functions as an inhibitor of autophagy by interacting with BECN1 and AMBRA1 during non-starvation conditions . Additionally, research suggests BCL2 may attenuate inflammation by impairing NLRP1-inflammasome activation, thereby inhibiting CASP1 activation and IL1B release .

What are the major BCL2 antibody clones available for research applications?

Research laboratories typically employ several monoclonal antibodies targeting BCL2, each recognizing different epitopes of the protein. The most commonly used antibodies include:

• Clone 124 (mouse monoclonal) - Historically the standard antibody used in clinical and research settings

• Clone E17 (rabbit monoclonal) - Targets a different epitope than the 124 clone

• Clone SP66 (rabbit monoclonal) - Provides enhanced detection capabilities compared to 124

• Clone Bcl2/100 (mouse monoclonal) - Targets amino acids 1-100 of human BCL2

Each of these antibodies has distinct applications and limitations in experimental workflows. For instance, the 124 clone exhibits well-documented limitations in detecting certain BCL2 variants, particularly in diffuse large B-cell lymphoma (DLBCL) samples with genetic alterations .

How do different BCL2 antibody clones compare in immunohistochemical detection?

Significant variations exist in the detection capabilities of different BCL2 antibody clones, particularly in the context of DLBCL research. In comparative studies of formalin-fixed, paraffin-embedded DLBCL tissues, the SP66 and E17 antibodies demonstrated substantially higher detection rates than clone 124 . Specifically:

Complete agreement across all three antibodies occurred in only 53% of DLBCL cases, with 19% (18/94) being BCL2-negative and 34% (32/94) BCL2-positive with all three antibodies . Notably, 47% (44/94) of cases showed discordant results, with clone 124 showing negative staining while E17 and/or SP66 detected BCL2 expression . This discrepancy is particularly significant in translocation-positive, amplification-positive, and activated B-cell DLBCL cases, where clone 124's failure to detect BCL2 could lead to misclassification of high-risk patients .

What mechanisms contribute to false-negative BCL2 detection with the standard 124 clone?

The 124 clone's failure to detect BCL2 expression in certain DLBCL cases stems from multiple mechanisms:

• BCL2 Phosphorylation: Phosphorylation of BCL2 at threonine 69 (T69) and/or serine 70 (S70) is more common in cases with discrepant staining between different antibody clones . This post-translational modification likely alters the epitope structure recognized by the 124 clone, preventing antibody binding.

• Genetic Mutations: Mutations within the epitope region targeted by the 124 clone can disrupt antibody binding, even when the BCL2 protein remains functionally intact and abundant . These mutations are particularly common in DLBCL cases, contributing to false-negative results despite the presence of t(14;18) translocations.

• Epitope Masking: In certain cellular contexts, protein-protein interactions or conformational changes may mask the epitope recognized by clone 124, while alternative epitopes detected by E17 and SP66 remain accessible .

Understanding these mechanisms is crucial for accurately interpreting BCL2 expression data and correctly stratifying DLBCL patients for prognostic and therapeutic purposes.

How can researchers optimize BCL2 detection in samples with genetic alterations?

For comprehensive BCL2 detection in research samples, particularly those with potential genetic alterations, researchers should implement a multi-faceted approach:

• Use multiple antibody clones: Employ at least two different antibody clones targeting different epitopes, such as combining the 124 clone with either E17 or SP66 . This strategy minimizes the risk of false negatives due to epitope-specific detection failures.

• Correlate with genetic studies: Combine protein detection with genetic analyses to assess BCL2 translocation and amplification status. Dual in situ hybridization (dual ISH) provides an effective tool for detecting these genetic alterations and can help validate ambiguous immunohistochemistry results .

• Assess phosphorylation status: In cases with discrepant staining patterns, evaluate BCL2 phosphorylation status at T69 and S70 using phospho-specific antibodies to determine if post-translational modifications are affecting antibody binding .

• Validate with alternative techniques: Confirm immunohistochemistry results using orthogonal methods such as Western blotting, flow cytometry, or mass spectrometry when possible .

This comprehensive approach ensures more accurate BCL2 detection, particularly in high-risk DLBCL cases where precise BCL2 status determination has significant prognostic and therapeutic implications.

What novel BCL2-targeting technologies are emerging in cancer research?

Several cutting-edge approaches targeting BCL2 are advancing therapeutic capabilities in oncology research:

• Small-molecule controlled switchable protein therapeutics: Researchers have developed an innovative "OFF-switch" system by computationally optimizing the affinity between BCL2 and a designed protein partner (LD3) . This engineered system enables heterodimer disruption upon addition of Venetoclax, a competing drug . This approach allows for spatiotemporal control of therapeutic activity, potentially reducing dose-limiting toxicities and adverse effects.

• PROTAC technology: Proteolysis targeting chimeras (PROTACs) represent a promising approach for targeting BCL2 by facilitating its selective degradation . This strategy involves creating bifunctional molecules that bridge BCL2 with E3 ubiquitin ligases, leading to polyubiquitination and subsequent proteasomal degradation of the target protein .

• Structure-guided mutagenesis: Research has revealed key residues within BCL2 that are critical for protein-protein interactions and drug binding. For example, mutations E136A/G128R and E136A/G128R/F124L in BCL2 disrupted ternary complex formation and prevented polyubiquitin chain formation in the context of PROTAC-mediated degradation . F124 was identified as a key residue supporting the hydrophobic patch created by Y98 (VHL) and the thiazol-benzyl moiety of the PROTAC molecule .

These emerging technologies provide new avenues for targeting BCL2 in cancer research and therapeutics, potentially overcoming resistance mechanisms associated with traditional approaches.

What experimental applications are best suited for different BCL2 antibody clones?

Different BCL2 antibody clones exhibit varied performance across experimental applications. When selecting an antibody, researchers should consider the specific requirements of their application:

Researchers should validate each antibody within their specific experimental system and consider using multiple antibodies targeting different epitopes to ensure comprehensive detection.

How should researchers interpret discrepant results between different BCL2 antibodies?

When encountering discrepant results between different BCL2 antibodies, researchers should follow these analytical approaches:

• Correlate with genetic data: Determine BCL2 translocation and amplification status using dual in situ hybridization or fluorescence in situ hybridization to establish whether BCL2 genetic alterations are present . This provides context for interpreting antibody staining results, particularly when standard antibodies like clone 124 yield negative results despite genetic evidence suggesting BCL2 overexpression.

• Examine post-translational modifications: Assess BCL2 phosphorylation status, particularly at T69 and S70 positions, which may affect epitope recognition by certain antibodies . This evaluation can explain discrepancies between antibody clones and provide insights into BCL2 regulation in the studied system.

• Consider epitope availability: Review the epitopes targeted by each antibody and evaluate whether protein interactions or conformational changes in your experimental system might affect epitope accessibility . The three-dimensional structure of BCL2 within cellular contexts may influence antibody binding efficacy.

• Evaluate assay conditions: Assess whether differences in sample preparation, fixation methods, or staining protocols could contribute to discrepant results . Optimization of these parameters may improve consistency across antibody clones.

In research publications, transparent reporting of the specific BCL2 antibody clone used, along with detailed methodological information, is essential for result interpretation and study reproducibility.

How are engineered BCL2-targeting antibodies advancing therapeutic applications?

The engineering of BCL2-targeting antibodies is evolving beyond simple detection tools to create sophisticated therapeutic agents:

• Switchable therapeutic antibodies: By incorporating engineered OFF-switch systems into therapeutic antibodies, researchers have developed controllable biologics with drug-induced deactivation capabilities . For example, the incorporation of an engineered BCL2-binding domain into anti-CTLA4, anti-HER2 antibodies, or an Fc-fused IL-15 cytokine demonstrated efficient disruption in vitro and fast clearance in vivo upon Venetoclax administration . This approach provides spatiotemporal control over antibody activity, potentially minimizing side effects.

• Rational design approaches: Computational methods like the Rosetta modeling suite enable optimization of protein-protein interactions, such as the affinity between BCL2 and designed binding partners . This rational design approach facilitates the development of antibodies with precise binding characteristics and controlled response to small-molecule modulators.

• Structure-guided modifications: Crystal structures of BCL2 in complex with therapeutic compounds provide insights for developing more effective targeting strategies . By identifying key interaction residues, researchers can design antibodies that target specific functional domains of BCL2 with enhanced specificity and efficacy.

These advancements represent the frontier of BCL2 antibody research, moving beyond detection applications toward therapeutically relevant engineered proteins with sophisticated control mechanisms.

What are the implications of BCL2 detection accuracy for precision medicine?

The accurate detection of BCL2 expression has profound implications for precision medicine approaches in oncology:

As precision medicine continues to evolve, the need for accurate BCL2 detection methodologies will become increasingly important for enabling tailored therapeutic approaches based on individual patient characteristics.